Evidence map›Paper›PMID 34608370›Full record

ArticleSaudi journal of biological sciences2021

Potential role of nicotinamide analogues against SARS-COV-2 target proteins.

Mandeep Kumar Arora, Parul Grover, Syed Mohammed Basheeruddin Asdaq, Lovekesh Mehta, Ritu Tomar, Mohd Imran, Anuj Pathak, Ashok Jangra, Jagannath Sahoo, Abdulhakeem S Alamri and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Saudi journal of biological sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Molecules (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Mandeep Kumar AroraSchool of Pharmaceutical and Population Health Informatics, DIT University, Dehradun 248009, Uttarakhand, India.
Parul GroverKIET School of Pharmacy, KIET Group of Institutions, Delhi-NCR, Ghaziabad 201206, India.
Syed Mohammed Basheeruddin AsdaqDepartment of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Dariyah, 13713 Riyadh, Saudi Arabia.
Lovekesh MehtaAmity Institute of Pharmacy, Amity University, Noida, 201301, India.
Ritu TomarSchool of Pharmaceutical and Population Health Informatics, DIT University, Dehradun 248009, Uttarakhand, India.
Mohd ImranDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Rafha, Saudi Arabia.
Anuj PathakKIET School of Pharmacy, KIET Group of Institutions, Delhi-NCR, Ghaziabad 201206, India.
Ashok JangraDepartment of Pharmaceutical Sciences, Central University of Haryana, Mahendergarh, Haryana 123031, India.
Jagannath SahooSchool of Pharmaceutical and Population Health Informatics, DIT University, Dehradun 248009, Uttarakhand, India.
Abdulhakeem S AlamriDepartment of Clinical Laboratory Sciences, The Faculty of Applied Medical Sciences, Taif University, Taif, Saudi Arabia.
Walaa F AlsanieDepartment of Clinical Laboratory Sciences, The Faculty of Applied Medical Sciences, Taif University, Taif, Saudi Arabia.
Majid AlhomraniDepartment of Clinical Laboratory Sciences, The Faculty of Applied Medical Sciences, Taif University, Taif, Saudi Arabia.
Dehradun Institute of Technology University · INTaif University · SAAlmaarefa UniversityAmity University · INCentral University of Haryana · INNorthern Border University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveCoronavirus 2019 (COVID-19) is caused by 'severe acute respiratory syndrome coronavirus 2' (SARS-CoV-2), first reported in Wuhan, China in December 2019, which eventually became a global disaster. Various key mediators have been reported in the pathogenesis of COVID-19. However, no effective pharmacological intervention has been available to combat COVID-19 complications. The present study screens nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) as potential inhibitors of this present generation coronavirus infection using an in-silico approach. MATERIALS AND

methodsThe SARS-CoV-2 proteins (nucleocapsid, proteases, post-fusion core, phosphatase, endoriboruclease) and ACE-2 protein were selected. The 2D structure of nicotinamide ribonucleoside and nicotinamide ribonucleotide was drawn using ChemDraw 14.0 and saved in .cdx format. The results were analyzed using two parameters: full fitness energy and binding free energy (ΔG).

resultsThe full fitness energy and estimated ΔG values from docking of NM, and NMN with selected SARS-CoV-2 target proteins, ADMET prediction and Target prediction indicate the interaction of NR and NMN in the treatment of COVID-19.

conclusionsBased on full fitness energy and estimated ΔG values from docking studies of NM and NAM with selected SARS-CoV-2 target proteins, ADME prediction, target prediction and toxicity prediction, we expect a possible therapeutic efficacy of NR in the treatment of COVID-19.

Indexed as

COVID-19Molecular dockingNicotinamidePoly (ADP-ribose) polymerase enzymeSARS-CoV-2

Identifiers

PMID34608370
PMCPMC8482651
OpenAlexW3203566344

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.